Literature DB >> 17651830

Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine.

Shao Liang Chen1, Junjie Zhang, Fei Yei, Zhongsheng Zhu, Zhizhong Liu, Song Lin, Jun Chu, Ji Yan, Ruiyan Zhang, Tak W Kwan.   

Abstract

BACKGROUND: The potential role of hydration in prevention of contrast-induced nephropathy (CIN) still remains to be unclear.
METHODS: Nine-hundred and thirty-six patients scheduled for percutaneous coronary intervention (PCI) were enrolled into the present study, and divided into normal (serum creatinine<1.5 mg/dl) and abnormal (serum creatine> or =1.5 mg/dl) groups according to their baseline serum concentration of creatinine. Each group was further randomly divided into two subgroups: hydration and nonhydration. All patients in abnormal group took twice orally loading dose of 1200 mg acetylcysteine (ATLS) at 12 h before scheduled time for coronary angiogram and immediately after procedure. Creatinine concentration was remeasured at the time of admission (just before catheterization), every day for the following three days. The primary end point during 6-month follow-up included clinical driven revascularization (either PCI or CABG), death from all causes, and requiring emergency renal-replacement therapy.
RESULTS: The incidence of CIN was more commonly in abnormal group that in normal group (6.52% vs. 37.68%, p<0.001). Hydration had potentials in prevention of CIN only in patients with elevated baseline concentration of creatinine. Multivariate analysis demonstrated that the following variables remained to be significant factors correlating with CIN: age> or =70 years (odds ration [OR] 5.27, 95% confidence interval [CI] 1.94 to 13.07, p=0.0007), contrast volume> or =320 ml (OR 3.26, 95% CL 2.14 to 7.58, p=0.01), diabetes mellitus (OR 9.86, 95% CL 5.38 to 31.67, p<0.0001), and peripheral arterial disease (OR 11.25, 95% CL 5.12 to 43.19, p<0.0001). Patients with CIN in abnormal group had worse clinical outcomes, compared to patients with CIN in normal group.
CONCLUSION: Patients with CIN and preexisting renal insufficiency had worse clinical outcomes. Hydration with 0.45% sodium chloride alone had no potential effect on the occurrence of CIN in patients with normal renal function. Combination of hydration with ATLS could reduce the incidence of CIN in patients at high risk.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17651830     DOI: 10.1016/j.ijcard.2007.05.004

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  28 in total

1.  Effects of Intra-Arterial and Intravenous Iso-Osmolar Contrast Medium (Iodixanol) on the Risk of Contrast-Induced Acute Kidney Injury: A Meta-Analysis.

Authors:  Peter A McCullough; Jeremiah R Brown
Journal:  Cardiorenal Med       Date:  2011-10-04       Impact factor: 2.041

2.  Short-term rosuvastatin therapy prevents contrast-induced acute kidney injury in female patients with diabetes and chronic kidney disease: a subgroup analysis of the TRACK-D study.

Authors:  Jing Li; Yi Li; Biao Xu; Guoliang Jia; Tao Guo; Dongmei Wang; Kai Xu; Jie Deng; Yaling Han
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

3.  Diabetes mellitus does not affect the incidence of acute kidney injury after cardiac surgery; a nested case-control study.

Authors:  Maria Moschopoulou; Foteini Ch Ampatzidou; Charalampos Loutradis; Afroditi Boutou; Charilaos-Panagiotis Koutsogiannidis; Georgios E Drosos; Pantelis A Sarafidis
Journal:  J Nephrol       Date:  2016-02-29       Impact factor: 3.902

4.  Left ventricular end-diastolic pressure-guided hydration for the prevention of contrast-induced acute kidney injury in patients with stable ischemic heart disease: the LAKESIDE trial.

Authors:  Armin Marashizadeh; Hamid Reza Sanati; Parham Sadeghipour; Mohamad Mehdi Peighambari; Jamal Moosavi; Omid Shafe; Ata Firouzi; Ali Zahedmehr; Mohsen Maadani; Farshad Shakerian; Reza Kiani; Bahram Mohebbi; Mohammad Javad Alemzadeh-Ansari; Reza Tahvili; Batoul Naghavi
Journal:  Int Urol Nephrol       Date:  2019-07-22       Impact factor: 2.370

5.  N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial.

Authors:  Manouchehr Amini; Mojtaba Salarifar; Alireza Amirbaigloo; Farzad Masoudkabir; Fatemeh Esfahani
Journal:  Trials       Date:  2009-06-29       Impact factor: 2.279

Review 6.  Prevention of acute kidney injury and protection of renal function in the intensive care unit. Expert opinion of the Working Group for Nephrology, ESICM.

Authors:  Michael Joannidis; Wilfred Druml; Lui G Forni; A B Johan Groeneveld; Patrick Honore; Heleen M Oudemans-van Straaten; Claudio Ronco; Marie R C Schetz; Arend Jan Woittiez
Journal:  Intensive Care Med       Date:  2010-03       Impact factor: 17.440

7.  Risk factors for contrast induced nephropathy: a study among Italian patients.

Authors:  Salvatore Evola; Monica Lunetta; Francesca Macaione; Giuseppe Fonte; Gaspare Milana; Egle Corrado; Francesca Bonura; Giuseppina Novo; Enrico Hoffmann; Salvatore Novo
Journal:  Indian Heart J       Date:  2012-07-27

8.  Contrast-induced nephropathy in patients undergoing percutaneous coronary intervention.

Authors:  Sana Shoukat; Saqib A Gowani; Asif Jafferani; Sajid H Dhakam
Journal:  Cardiol Res Pract       Date:  2010-09-19       Impact factor: 1.866

9.  Contrast-induced nephropathy in patients with chronic kidney disease and peripheral arterial disease.

Authors:  Christian Kroneberger; Christian N Enzweiler; Andre Schmidt-Lucke; Ralph-Ingo Rückert; Ulf Teichgräber; Tobias Franiel
Journal:  Acta Radiol Open       Date:  2015-06-24

10.  Changes in renal function in elderly patients following intravenous iodinated contrast administration: a retrospective study.

Authors:  Ali Alsafi; Zaid Alsafi; Amish Lakhani; Nicola H Strickland
Journal:  Radiol Res Pract       Date:  2014-03-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.